Summary
The Federal Trade Commission and seven states say Shkreli should be held in contempt
‘Pharma Bro’ Martin Shkreli is in trouble with regulators again, this time for influencing biopharma stocks
Source & full coverage: this summary is aggregated from MarketWatch, the original publisher. Read the complete report for full context, data and quotes.
Read the original report at MarketWatch →
